Retrospective Analysis Suggests Allo-HSCT Feasible for R/R D

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

Related Keywords

China , Abbvie Roche , Pharmacyclics Janssen , First Affiliated Hospital Of Soochow University , Experimental Hematology , First Affiliated Hospital , Soochow University , Rr Dlbcl , Dlbcl , Allo Hsct , Agvhd ,